26 May 2026

strategyland.uk

AstraZeneca PLC (AZN)

Rank #72 of 100 - Healthcare - UK Equities

Home/Stocks/Healthcare

AstraZeneca PLC

AZN.L·Healthcare·Market Cap £216.4b

Rank #72 of 100

Data from Excel Model · 100 Stocks Analysed

£138.86

+1.16% YTD

Target: £167.02(+20.3%)

52W: £101.03 - £157.32

Score Analysis

AstraZeneca PLC is ranked #72 out of 100 UK stocks. Lower factor scores indicate better performance in that category.

Factor Breakdown

46/100

Average Score

Liquidity

Fair41/100

Valuation

Weak76/100

Profitability

Weak93/100

Solvency

Excellent10/100

Asset Efficiency

Weak85/100

Mkt Trading

Excellent10/100

Technical

Excellent10/100

1. Valuation

Score: 76/100

Is AZN undervalued compared to its peers and fair value metrics?

0/5

valuation criteria met

✗

FY26e P/E Ratio

18.3xRank 76/100

✗

FY27e P/E Ratio

16.3xRank 75/100

✗

Price-to-Book

5.92xRank 82/100

✗

Price-to-Tangible Book

N/ARank 101/100

✗

EV/EBITDA

15.8xRank 81/100

Key Valuation Metrics

Current P/E

28.1x

Price-to-Earnings

FY26e P/E

18.3x

Forward estimate

FY27e P/E

16.3x

Forward estimate

P/B Ratio

5.92x

Price-to-Book

P/TBV

N/A

Price-to-Tangible Book

EV/EBITDA

15.8x

Enterprise Value

FY26e EV/EBITDA

13.3x

Forward estimate

FY27e EV/EBITDA

13.3x

Forward estimate

Analyst Consensus Target

Current Price

£138.86

Consensus Target

£167.02

Potential

+20.3%

Target

Bloomberg Median Target: £165.15

2. Profitability

Score: 93/100

How profitable is AZN relative to its peers?

0/6

profitability criteria met

✗

TTM Profit Margin

17.2%Rank 62/100

–

Current ROE

22.9%

–

Current ROA

N/A

✗

FY26e EPS

11.55Rank 94/100

–

TTM EPS

10.80

–

Net Income Growth

N/A

Profit Margin

17.2%

ROE

22.9%

FY27e ROE

29.1%

ROA

N/A

Earnings Per Share

3. Financial Health

Score: 10/100

How strong is AZN's balance sheet and financial position?

0/4

solvency criteria met

–

Debt-to-Equity

60.8%

–

Interest Coverage

N/A

✗

Debt/EBITDA

Rank 66Rank 66/100

–

Altman Z-Score

3.75

Key Health Metrics

Quick Ratio

0.72

Below 1.0

Cash Ratio

0.94

Debt/Equity

61%

FCF Margin

5.1%

Altman Z-Score

3.75

Safe Zone

01.812.995+

4. Asset Efficiency

Score: 85/100

How efficiently does AZN deploy its assets and intellectual capital?

1/2

asset efficiency criteria met

–

Intangible/Asset

Intangible assets as a proportion of total assets — lower indicates more tangible, capital-efficient operations

N/A

✓

R&D/Sales

Research & development spend relative to revenue — balanced R&D investment signals sustainable growth

Rank 1/100

Overall Asset Efficiency Rank

Rank within sector peers#85/100

Best (1)Worst (100)

What This Measures

Intangible/Asset — a lower ratio suggests the company's value is backed by tangible assets rather than goodwill or intangibles, reducing balance sheet risk.

R&D/Sales — captures the proportion of revenue reinvested into research and development, indicating innovation intensity and future growth investment.